Senator Bernie Sanders, I-Vermont, has claimed his Medicare-for-all plan will cut healthcare spending by $2 trillion, but fact checking shows that's unlikely; CVS' CEO defends its pharmacy benefit manager against claims rebates are driving up drug prices; researchers have found that immigrants have healthcare costs that are half to two-thirds of the costs of people born in the United States.
Senator Bernie Sanders, I-Vermont, has made big claims about the savings Americans will enjoy under his Medicare-for-all plan, but he might be overlooking some facts. The Associated Press fact checked Sanders’ claims and noted that his claim that the plan will cut $2 trillion from the country’s healthcare bill is reliant on a scenario of significantly lower payments to hospitals and doctors for most patients. The reality is that if providers are paid the same under the plan, spending would increase by more than $3 trillion.
The Trump administration has criticized high drug prices and rebates paid to pharmacy benefit managers like Caremark, owned by CVS Health, for driving up prices. Larry Merlo, the CEO of CVS, is defending against the blame, noting that prices of drugs with smaller rebates are actually rising the fastest, reported The Wall Street Journal. Merlo said that 98% of the tens of billions of dollars his company has generated through rebates are passed through to clients—insurers, companies, and groups that pay for medicines.
Researchers from Harvard Medical School and Tufts University have found that immigrants have healthcare costs that are half to two-thirds of the costs of people born in the United States. According to The Hill, immigrants make up 12% of the population, but they account for only 8.6% of the country’s healthcare spending. Undocumented immigrants, who make up 5% of the population, account for only 1.4% of total spending.
Telephone Follow-Up on Medicare Patient Surveys Remains Critical
January 16th 2025Including a telephone component in Medicare Consumer Assessment of Healthcare Providers and Systems survey administration continues to be valuable because telephone responses comprise a substantial portion of responses for several underserved groups.
Read More
Quantifying the Altruism Value for a Rare Pediatric Disease: Duchenne Muscular Dystrophy
January 14th 2025Altruism values for treatments of rare, severe pediatric diseases have not been estimated. This study found the altruism value for a hypothetical new Duchenne muscular dystrophy treatment to be $80 per year.
Read More
Health Equity & Access Weekly Roundup: January 11, 2025
January 11th 2025ACA enrollment rate hits a milestone, though IRA subsidies may not extend beyond 2025; network adequacy standards fail to translate into efficient access to mental health care for Medicaid enrollees; research examines racial disparities in postpartum hypertension and vaccine uptake.
Read More